Hillsborough, NJ, United States of America

Stephen Soisson


Average Co-Inventor Count = 18.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):

Title: Stephen Soisson: Innovating PCSK9 Antagonists in Hillsborough, NJ

Introduction

Stephen Soisson, a dedicated inventor based in Hillsborough, NJ, is known for his significant contribution to the field of biopharmaceuticals. His innovative work revolves around PCSK9 antagonists, which play a vital role in addressing conditions associated with PCSK9 activity.

Latest Patents

Soisson holds one patent titled "AX132 PCSK9 antagonists." This groundbreaking patent discloses antagonists of human proprotein convertase subtilisin-kexin type 9 (PCSK9). The disclosed antagonists are effective in inhibiting PCSK9 function, which presents promising therapeutic options for various medical conditions. Additionally, Soisson's patent includes nucleic acid encoding for these antagonists, along with vectors, host cells, and compositions that comprise these innovative antagonists. Notably, the patent outlines methods for the production of PCSK9-specific antagonists and their applications in clinical settings.

Career Highlights

Stephen Soisson is associated with Merck Sharp & Dohme Corporation, a prominent player in the pharmaceutical industry, where he has been able to turn his inventive ideas into tangible solutions that can improve patient outcomes. His work contributes to the ongoing development of therapies aimed at managing conditions related to lipid metabolism and cholesterol management.

Collaborations

Throughout his career, Soisson has collaborated with fellow researchers, including Peter Peizhi Luo and Kevin Caili Wang. These collaborations underscore the collaborative nature of innovation in pharmaceuticals, as experts come together to further the understanding and application of new treatments.

Conclusion

In summary, Stephen Soisson's contributions to the development of PCSK9 antagonists mark a significant advancement in the treatment of related health conditions. His patent serves as a testament to his commitment to innovation and the improvement of therapeutic options. Through his work at Merck Sharp & Dohme Corporation, Soisson continues to push the boundaries of what's possible in the realm of biomedicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…